HighField Biopharmaceuticals focuses on developing innovative therapies utilizing advanced biopharmaceutical technologies. The company specializes in the creation of monoclonal antibodies and other biologics, which are designed to target specific diseases with high precision. Their pipeline includes a range of products aimed at addressing unmet medical needs in various therapeutic areas, showcasing their commitment to improving patient outcomes through cutting-edge science.

The technologies employed by HighField Biopharmaceuticals encompass a robust platform for drug discovery and development, leveraging techniques such as recombinant DNA technology and protein engineering. This allows for the optimization of therapeutic candidates, enhancing their efficacy and safety profiles. Additionally, the company emphasizes the importance of rigorous preclinical and clinical testing to ensure that their products meet the highest standards of quality and effectiveness before reaching the market.

China

Clinical stage immuno-oncology company focused on novel applications of liposome constructs to disrupt existing immuno-oncology technologies. The company's lead clinical development program is HF1K16, a drug encapsulated immune modulating liposome of all-trans retinoic acid targeting myeloid-derived suppressor cells for treatment of solid tumor cancers.

Additional programs include immunoliposomes designed to improve efficacy and toxicity of existing of existing immuno-oncology technologies including ADCs and CAR-T.

HighField Biopharmaceuticals

Company Details